首页> 外国专利> Composition of single nucleotide polymorphism markers for predicting prognosis of ulcerative colitis in Asians and method for predicting prognosis of ulcerative colitis using the same

Composition of single nucleotide polymorphism markers for predicting prognosis of ulcerative colitis in Asians and method for predicting prognosis of ulcerative colitis using the same

机译:预测亚洲人溃疡性结肠炎预后的单核苷酸多态性标记物的组成及其使用的预测溃疡性结肠炎预后的方法

摘要

The present invention relates to a single nucleotide polymorphism marker composition for predicting prognosis of ulcerative colitis in Asians and a method for predicting the prognosis of ulcerative colitis using the same. According to the present invention, an analysis in a case is performed using representation data of 587 ulcerative colitis patients (bad prognosis cases of 463 people and good prognosis cases of 124 people) and three independent cohorts-cased HLA fine-mapping data about 1,324 ulcerative colitis patients (bad prognosis cases of 972 people and good prognosis cases of 352 people). Also, modification of rs9268877 SNP related to the prognosis of ulcerative colitis is confirmed. Therefore, according to the present invention, the single nucleotide polymorphism marker composition can be usefully used to perform patient-specific treatment and establish a treatment strategy to diagnose the prognosis of ulcerative colitis.
机译:本发明涉及用于预测亚洲人溃疡性结肠炎的预后的单核苷酸多态性标记物组合物,以及使用该组合物来预测溃疡性结肠炎的预后的方法。根据本发明,使用587例溃疡性结肠炎患者的代表数据(不良预后为463人,良好预后为124人)和三个独立的队列病例HLA精细映射数据进行病例分析,所述病例为约1324例溃疡性结肠炎。结肠炎患者(不良预后972人,好预后352人)。而且,证实了与溃疡性结肠炎的预后有关的rs9268877 SNP的修饰。因此,根据本发明,单核苷酸多态性标志物组合物可有效地用于进行患者特异性治疗并建立诊断溃疡性结肠炎的预后的治疗策略。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号